NASDAQ:SILK • US82710M1009
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SILK ROAD MEDICAL INC (SILK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-07-17 | Stifel | Downgrade | Buy -> Hold |
| 2024-07-11 | Argus Research | Downgrade | Buy -> Sell |
| 2024-06-18 | Lake Street | Downgrade | Buy -> Hold |
| 2024-05-01 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-05-01 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-03-07 | Argus Research | Upgrade | Hold -> Buy |
| 2024-02-29 | Stifel | Maintains | Buy -> Buy |
| 2024-02-29 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-02-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-01-19 | Stifel | Upgrade | Hold -> Buy |
| 2024-01-03 | Lake Street | Initiate | Buy |
| 2023-10-24 | Wolfe Research | Upgrade | Underperform -> Peer Perform |
| 2023-10-11 | CL King | Downgrade | Buy -> Neutral |
| 2023-10-11 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-10-11 | Stifel | Downgrade | Buy -> Hold |
| 2023-10-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2023-10-11 | Citigroup | Downgrade | Buy -> Sell |
| 2023-09-21 | Argus Research | Downgrade | Buy -> Hold |
| 2023-09-06 | Oppenheimer | Initiate | Outperform |
| 2023-08-14 | Citigroup | Maintains | Buy -> Buy |
| 2023-08-02 | B. Riley Securities | Maintains | Buy -> Buy |
| 2023-08-02 | Stifel | Maintains | Buy -> Buy |
| 2023-07-12 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2023-07-12 | B of A Securities | Downgrade | Buy -> Underperform |
| 2023-07-11 | Citigroup | Reiterate | Buy -> Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 101.5M 34.97% | 138.6M 36.55% | 177.134M 27.80% | 203.98M 15.16% | 226.77M 11.17% | 249.32M 9.94% | 290.9M 16.68% | |
| EBITDA YoY % growth | -46.47M -10.35% | -49.87M -7.32% | -56.575M -13.44% | -37.291M 34.09% | -26.663M 28.50% | -18.054M 32.29% | N/A | |
| EBIT YoY % growth | -47.5M -10.72% | -52M -9.47% | -59.271M -13.98% | -60.11M -1.42% | -55.21M 8.15% | -50.85M 7.90% | -48.144M 5.32% | |
| Operating Margin | -46.80% | -37.52% | -33.46% | -29.47% | -24.35% | -20.40% | -16.55% | |
| EPS YoY % growth | -1.44 | -1.54 -6.94% | -1.44 6.49% | -1.49 -3.77% | -1.34 10.24% | -1.26 5.70% | -1.20 4.84% |
All data in USD
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 -8.18% | -0.35 -5.09% | -0.39 -9.08% | -0.32 23.09% | -0.31 14.29% | -0.28 19.61% |
| Revenue Q2Q % growth | 50.249M 13.08% | 52.302M 10.65% | 53.087M 9.49% | 55.959M 9.21% | 55.521M 10.49% | 59.857M 14.44% |
| EBITDA Q2Q % growth | -15.83M -36.12% | -7.371M 36.87% | -10.941M 23.43% | -6.63M 58.27% | -6.63M 58.12% | -6.12M 16.97% |
| EBIT Q2Q % growth | -15.991M -16.98% | -14.121M 1.74% | -14.833M 0.68% | -12.534M 27.11% | -12.007M 24.91% | -11.612M 17.77% |
All data in USD
13 analysts have analysed SILK and the average price target is 22.54 USD. This implies a price decrease of -18% is expected in the next year compared to the current price of 27.49.
SILK ROAD MEDICAL INC (SILK) will report earnings on 2024-11-06, after the market close.
The consensus EPS estimate for the next earnings of SILK ROAD MEDICAL INC (SILK) is -0.36 USD and the consensus revenue estimate is 50.25M USD.
The consensus rating for SILK ROAD MEDICAL INC (SILK) is 49.2308 / 100 . This indicates that analysts generally have a neutral outlook on the stock.